Welcome Message

Message from Rob Quinn MD PhD FRCPC
President North American Chapter


Almost one year has passed since I took over as President of the North American Chapter. I’m extremely proud of what we have been able to accomplish so far and excited to see what the next year brings. I’d like to thank the members of the executive council and our subcommittee members for their enthusiasm and hard work.

The North American PD Catheter Registry, a CIHR-funded study involving 22 sites in Canada and the U.S. finished recruitment and follow-up on December 31, 2023. We are finalizing the dataset for the main analysis that will look at the association between method of insertion and operator volume and catheter outcomes. A number of additional projects have leveraged the dataset. CJASN recently published a paper led by Dr. Qureshi and Dr. Oliver that showed people with intra-abdominal adhesions undergoing PD catheter insertion were at higher risk for abdominal pain or flow restriction that led to PD termination and invasive procedures. However, most patients, with or without adhesions, did not experience complications, and most complications did not lead to the termination of PD therapy. AJKD recently accepted an analysis led by Dr. Khan and Dr. Quinn that examined the association between prior abdominal procedures and catheter outcomes. Prior abdominal procedures were not associated with a significantly increased risk of catheter-related complications that led to abandonment of the PD catheter, interruption/termination of PD, or emergency room visits, hospitalizations, or procedures.

The North American Chapter (NAC) has also launched its first research fellowship competition. The successful candidate will be a nephrology or home dialysis fellow in a North American Program, an ISPD NAC member, and have dedicated research time. They will have an interest in pursuing home dialysis research. The winner will receive a year-long research mentorship program, access to data from the North American PD Catheter Registry, and a $5,000 stipend to cover study-related costs. Interested applicants should forward a curriculum vitae, two reference letters, a letter outlining their proposed research question and motivation for applying to this award, as well as a letter of support from their fellowship director that confirms that they will have protected time for
research to ispdnac@gmail.com by April 1st, 2024. The award will begin July 1st, 2024.

We invite you to participate in our ISPD NAC Journal Clubs that discuss important studies in PD and are ongoing in 4 times zones (Pacific, Mountain, Central, and Eastern). Details and contact information are available on the ISPD-NAC website. Our education committee is also developing some new content around professional development and will be hosting a series on how to write an abstract, write a scientific paper, and design and deliver an oral presentation.

Our program committee has been hard at work collaborating on content for upcoming, in-person meetings including our annual ISPD North American Chapter at the Annual Dialysis Conference day in San Diego. Please be sure to join us there for an informative, entertaining, and educational day.

Finally, we are expanding our social media presence. Please join us on X (formerly Twitter) @ispd_nac and stay tuned for further updates.

As always, if you would like to get more involved, please don’t hesitate to reach out to myself or any member of the ISPD NAC Executive Council.

Dr. Rob Quinn MD PhD
Nephrologist and Professor of Medicine
University of Calgary, Calgary, Canada



Message from Rob Quinn – NAC President – Welcome message

Message from Thomas Golper – Immediate Past President – Welcome Message

Message from Matthew Oliver – Past President – Welcome Message

Message from Anjali Saxena – Past President- Welcome message

Message from Rajnish Mehrotra – Past President – Mid term

Message from Rajnish Mehrotra – Past-President – Welcome message

Message from Peter Blake – Past President – Welcome Message

ISPD – NAC announces with regret the death of  Jose Diaz-Buxo

Letter to Federal Drug Administration Agency